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Summary
The combination of lenalidomide–dexamethasone is active in multiple
myeloma (MM). Preclinical data showed that the Akt inhibitor, perifosine,
sensitized MM cells to lenalidomide and dexamethasone, providing the
rationale for this Phase I, multicentre, single-arm study to assess the safety
and determine the maximum-tolerated dose (MTD) of perifosine–lenalido-
mide–dexamethasone in relapsed and relapsed/refractory MM. Patients
received escalating doses of perifosine 50–100 mg daily and lenalidomide
15–25 mg once daily on days 1–21 of each 28-d cycle, plus dexamethasone
20–40 mg weekly thereafter, as indicated. Thirty-two patients were enrolled
across four dose cohorts. MTD was not reached, with 31 patients evaluable
for safety/tolerability. The most common all-causality grade 1-2 adverse
events were fatigue (48%) and diarrhoea (45%), and grade 3–4 neutropenia
(26%), hypophosphataemia (23%), thrombocytopenia (16%), and leuco-
penia (13%). Among 30 evaluable patients, 73% (95% confidence interval,
57·5–89·2%) achieved a minimal response or better, including 50% with a
partial response or better. Median progression-free survival was
10·8 months and median overall survival 30·6 months. Response was asso-
ciated with phospho-Akt in pharmacodynamic studies. Perifosine–lenalido-
mide–dexamethasone was well tolerated and demonstrated encouraging
clinical activity in relapsed and relapsed/refractory MM.
Keywords: perifosine, lenalidomide, dexamethasone, relapsed multiple
myeloma, Akt.
Novel agents, such as thalidomide, bortezomib and lenalido-
mide, used as single agents or in combination, have
improved the clinical outlook for patients with relapsed and/
or refractory multiple myeloma (MM) (Richardson et al,
2005, 2007a; Dimopoulos et al, 2007; Kropff et al, 2007;
Orlowski et al, 2007; Weber et al, 2007; Kumar et al, 2008;
Palumbo et al, 2008; Knop et al, 2009; Laubach et al, 2009).
However, patients who relapse following therapy with these
agents tend to have a particularly poor prognosis; therefore,
additional classes of novel agents are required to improve
patient outcome and survival (Kumar et al, 2009).
There is a rationale for inhibiting the Akt signalling
pathway in patients with MM, as it promotes cell survival
and proliferation, and mediates MM cell resistance to con-
ventional therapeutics (Hideshima et al, 2001, 2004). Pe-
rifosine (KRX-0401; Keryx Biopharmaceuticals, Inc., NY,
USA) is a novel, oral signal transduction modulator with
multiple pathway effects, including Akt inhibition and
activation of c-Jun N-terminal kinase (Hideshima et al,
2006). Preclinical data have shown that perifosine inhib-
its phosphorylation of Akt, induces cytotoxicity, and
increases dexamethasone-, doxorubicin-, melphalan-, and
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bortezomib-induced cytotoxicity in MM cells (Hideshima
et al, 2006).
In Phase II studies of patients with relapsed/refractory
MM, perifosine in combination with dexamethasone, or
dexamethasone plus bortezomib, has demonstrated accept-
able tolerability and promising clinical activity, suggesting
that it may augment the efficacy of established treatment
regimens (Richardson et al, 2007b, 2008, 2011). This possi-
bility is currently being assessed in a Phase III trial
comparing perifosine–bortezomib–dexamethasone versus
bortezomib–dexamethasone in relapsed/refractory patients
previously treated with bortezomib (www.clinicaltrials.gov
NCT01002248).
Lenalidomide–dexamethasone is another treatment regi-
men in patients with relapsed/refractory MM that could
potentially be augmented with the addition of perifosine.
Preclinical studies have provided the rationale for combining
lenalidomide with phosphatidylinositol 3-kinase/Akt pathway
inhibitors (Raje et al, 2004; Shi et al, 2005). Furthermore, in
vitro experiments in MM cell lines suggest that perifosine
may increase the cytotoxicity of lenalidomide–dexamethasone
(Jakubowiak et al, 2007).
In the preclinical portion of this study, we assessed the
impact of perifosine–lenalidomide–dexamethasone on cell
growth in MM cells (see Appendix S1, Table SI, and Fig
S1). Based on these analyses, a Phase I clinical study of
the 3-drug combination was conducted by the Multiple
Myeloma Research Consortium (MMRC; NCT00415064) in
patients with relapsed or relapsed/refractory MM (Ja-
kubowiak et al, 2008). The primary objectives of the trial
were to determine the safety, maximum tolerated dose
(MTD), and response rate.
Methods
Patients
Eligible patients were  18 years old with relapsed or
relapsed/refractory, measurable MM that required a second-
or third-line of therapy. Patients with refractory disease were
defined as progressing on treatment or within 60 d of last
treatment; patients refractory to thalidomide or thalidomide–
dexamethasone were eligible. Patients who had been treated
previously with either lenalidomide or dexamethasone were
also eligible, unless they were refractory to lenalidomide–
dexamethasone. Additional eligibility criteria included an
Eastern Cooperative Oncology Group (ECOG) performance
status of 0–2, adequate liver function (defined as aspartate
aminotransferase, alanine aminotransferase, and alkaline
phosphatase  3 times upper limit of normal, and biliru-
bin  upper limit of normal) and renal function (serum
creatinine  51·3 lmol/l), an absolute neutrophil
count  1·0 9 109/l, and a platelet count  75 9 109/l
within 14 d prior to enrolment.
Study design and treatment
This Phase I, multicentre, single-arm, open-label study was
conducted at six MMRC centres in the USA. Patients were
enrolled between December 2006 and June 2008. The study
was approved by local review boards, and was conducted in
accordance with the Declaration of Helsinki and the Interna-
tional Conference on Harmonization Guidelines for Good
Clinical Practice (World Medical Association, 2009). All
patients provided written informed consent prior to partici-
pation.
Patients received oral perifosine once daily with food in
the evening/at bedtime, oral lenalidomide on days 1–21,
and oral dexamethasone in 28-d cycles. At the end of cycle
8, a full disease assessment was performed. Patients who
responded or had stable disease were permitted to con-
tinue treatment until disease progression or unacceptable
toxicity.
There were four dose levels in the dose-escalation Phase of
the study. Dose level 1: perifosine 50 mg/d; lenalidomide
15 mg/d; dexamethasone 20 mg/d on days 1–4, 9–12, and
17–20 for the first four cycles, and 20 mg/d on days 1–4 of
subsequent cycles. Dose level 2: as level 1, except the lenalid-
omide dose was 25 mg/d. Dose level 3: perifosine 100 mg/d;
lenalidomide 15 mg/d; dexamethasone 40 mg once weekly
for the first four cycles and 20 mg per week for subsequent
cycles. Dose level 4: as level 3, except the lenalidomide dose
was 25 mg/d.
Six patients were planned to be enrolled at each dose level
and monitored for one cycle for dose-limiting toxicities
(DLTs). Once the MTD had been determined, an additional
six patients would be treated at that dose. In August 2007,
after the first 12 patients were enrolled (at dose levels 1 and
2), the protocol was amended to limit dexamethasone-related
adverse events (AEs) and followed a low-dose dexamethasone
regimen (40 mg weekly for cycle 1–4 and 20 mg weekly for
subsequent cycles), as described previously (Rajkumar et al,
2010a).
A DLT was defined as a grade  3 non-haematological
toxicity, grade 4 haematological toxicity (thrombocytopenia
with platelet count <25 9 109/l on more than one occasion
despite transfusion support, or grade 4 neutropenia lasting
>5 d and/or resulting in neutropenic fever), or an inability
to receive the day 1 dose in cycle 2 due to toxicity. The
MTD was defined as the dose level prior to that resulting in
a DLT, i.e. the dose level at which no more than one out of
up to six patients experienced a DLT.
After completion of cycle 1, dose modifications were per-
mitted based on investigator assessment of AEs. For persis-
tent grade 2 AEs, perifosine could be reduced from 100 mg/d
to 50 mg/d, or from 50 mg/d to 50 mg every other day. For
patients on lenalidomide 25 mg, the dose could be reduced
to 15 mg, with further 5 mg decrements to 5 mg/d, if
required. Dose adjustments of dexamethasone were at the
discretion of the treating investigator.
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Study objectives
The primary objectives of this study were to determine the
safety and the MTD of perifosine in combination with lena-
lidomide and dexamethasone, and also the response rate of
perifosine in combination with lenalidomide and dexametha-
sone, in patients with relapsed and relapsed/refractory MM.
The secondary objective was to observe the duration of
response of perifosine in combination with lenalidomide and
dexamethasone, in patients with relapsed and relapsed/refrac-
tory MM.
Safety, toxicity, and efficacy assessment
Toxicities were monitored by the investigators throughout
the trial and for up to 30 d after the last administration of
study medication. AEs were graded according to National
Cancer Institute Common Terminology for Adverse Events,
Version 3.0 (National Cancer Institute, 2006).
Efficacy was assessed by investigators according to the
modified European Group for Blood and Marrow Transplant
response criteria (Bladé et al, 1998). Response, defined as at
least minimal response (MR), was assessed after two cycles
and every cycle thereafter, and was classified according to the
International Uniform Response Criteria (IURC) (Durie et al,
2006) with an addition of MR and near complete response
(nCR). Assessments of response, relapse, and progression
were based on measurement of serum/urine M-protein levels
(at baseline and on day 1 of each cycle), bone marrow evalua-
tion, skeletal survey, and, if applicable, assessment of plasma-
cytoma.
Determination of phospho-Akt
Bone marrow core biopsies or aspirates were collected before
and after the first cycle from consenting patients and immu-
nohistochemically stained with an anti-phospho-Akt anti-
body (Ser473; Cell Signaling Technologies, Danvers, MA).
The percentage of neoplastic plasma cells [identified with an
anti-CD138 antibody (Cell Marque Corporation, Rocklin,
CA) and histopathological features] positive for phospho-Akt
was assessed by a haematopathologist in a blinded fashion.
High and low phospho-Akt-positive staining was defined as
>40% and  40% of stained plasma cells, respectively.
Statistical analysis
Safety was analysed in all patients who received at least one
dose of study medication. Observed response rates were
reported as percentages with 95% confidence intervals (CIs).
Progression-free survival (PFS) and overall survival (OS),
which were measured from the time of treatment initiation
to event, disease progression or death, were analysed using
log-rank tests. The Kaplan-Meier method was used to esti-
mate median times for PFS and OS, and the corresponding
95% CIs. For these survival analyses, data were censored as
of the cut-off date on 10 July 2011. The minimal level of sig-
nificance was P  0·05.
Results
Patient characteristics and disposition
Of 32 patients enrolled, 30 were evaluable for efficacy, and
31 for safety and tolerability. Baseline patient characteristics
are listed in Table I. Of evaluable patients, eight were thalid-
omide-naı̈ve and 22 had received prior thalidomide, of
whom 13 (59%) were refractory to thalidomide. In addition,
two patients had received prior lenalidomide, and 14 patients
had received prior bortezomib, of whom 6 (43%) had pro-
gressed on bortezomib. Of these six patients, four had pro-
gressed on bortezomib as the last line of therapy prior to this
study. Eight patients (27%) who otherwise met all other eli-
gibility criteria had three or four prior lines of therapy, based
on exceptions granted by the investigators.
Six patients received dose level 1, six received dose level 2,
eight received dose level 3 (two of 8 patients did not complete
cycle 1 due to non-compliance and a non-treatment-related
splenic aneurysm, respectively, and were not included in the
MTD assessment or the efficacy analysis), and six received
dose level 4. The median number of cycles received was 5·5
Table I. Patient characteristics and disposition at baseline.
Characteristic Patients (N = 32)
Male, n (%) 17 (53)
Median age, years (range) 64 (37–79)
Patient status, n (%)
Relapsed 17 (53)
Relapsed/refractory 15 (47)
Multiple myeloma type, n (%)
IgA 10 (31)
IgG 21 (66)
Kappa LC 1 (3)




Median lines of therapy, n (range) 2 (1–4)
Received  3 lines of therapy, n (%) 8 (27)




Autologous stem cell transplantation 23 (72)
Lenalidomide 2 (6)
VAD 8 (25)
Ig, immunoglobulin; VAD, vincristine, doxorubicin, dexamethasone.
*Of these patients, 15 (63%) were refractory to thalidomide/
dexamethasone (47% of all patients); two of these patients were
non-evaluable for efficacy.
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(range, 1–37). There were no DLTs at dose levels 1 and 2,
one DLT at dose level 3 (grade 3 nausea), and no DLTs at
dose level 4.The MTD was therefore not reached. However,
based on drug tolerability and cumulative toxicity beyond
cycle 1, plus emerging experience from other perifosine stud-
ies (Richardson et al, 2011), the maximum planned dose level
4 was used for an extension cohort of 12 patients in total.
Safety and tolerability
The most frequent all causality grade 1-2 AEs were fatigue
(48%), diarrhoea (45%), hyperglycaemia and nausea (32%
each). The most common grade 3–4 haematological AEs
were neutropenia (25%), thrombocytopenia (16%) leuco-
penia (13%), and lymphopenia (10%). The most common
grade 3–4 non-haematological AEs were hypophosphataemia
(23%), arthralgia (10%), and hyperglycaemia (10%). No
grade 3–4 peripheral neuropathy or deep vein thrombosis
were reported (Table II).
AEs were manageable with supportive care, dose reduc-
tions, or interruptions. Perifosine dose was reduced in nine
patients: one at dose level 3 due to rash; eight at dose level 4
due to diarrhoea (three patients), nausea (two patients), hy-
perglycaemia, upper respiratory infection, and anaemia (one
patient each). Lenalidomide dose was reduced in 11 patients:
one at dose level 1 due to thrombocytopenia; two at dose
level 2 due to thrombocytopenia and hypophosphataemia,
respectively; eight at dose level 4 due to thrombocytopenia
(three patients), hypophosphataemia (three patients), neutro-
penia, and anaemia (one patient each). Dexamethasone dose
was reduced in seven patients: one at dose level 1 due to psy-
chological changes; one at dose level 2 due to difficulty sleep-
ing; five at dose level 4 due to dizziness (two patients),
muscle pain (two patients), and abdominal bloating (one
patient). Two patients discontinued treatment after comple-
tion of cycle 1: one at dose level 3 due to grade 3 nausea;
one at dose level 4 due to persistent lenalidomide-related cy-
topenia. There were no treatment-related deaths.
Efficacy
Overall, 22 (73%) evaluable patients achieved at least a MR;
at least partial response (PR) rate [nCR/CR + very good par-
tial response (VGPR) + PR] was 50% (Table III), including
seven patients (23%) achieving a VGPR or better. The med-
ian time to first response was 1 cycle (range, 1–3 cycles); the
median duration of response was 9·2 months (range, 2–
35 months). In the subset of patients with relapsed but not
refractory disease (N = 17), at least PR was 71% and at least
MR was 82%; and in patients with refractory disease
(N = 13) at least PR was 23% and at least MR was 62%.
Among the thalidomide-exposed patients (N = 22), PR or
better was 45%, 78% in the thalidomide-relapsed patients (7
of 9), and 23% in the thalidomide-refractory patients (3 of
13). In the small subset of bortezomib-refractory patients,
Table II. Summary of the most common all-causality adverse
events*.
Adverse event (n = 31)
Grade 1 or 2,
n (%) >20% of
patients
Grade 3 or 4,
n (%)  10%
of patients
Haematological
Neutropenia – 8 (26)
Leucopenia – 4 (13)
Lymphopenia – 3 (10)
Thrombocytopenia 9 (29) 5 (16)
Anaemia 8 (26) 3 (10)
Non-haematological
Hypophosphataemia – 7 (23)
Arthralgia – 3 (10)
Fatigue 15 (48) –
Hyperglycaemia 10 (32) 3 (10)
Back pain – 3 (10)
Peripheral oedema 7 (23) –
Diarrhoea 14 (45) –
Nausea 10 (32) –
Vomiting 9 (29) –
Constipation 9 (29) –
Elevated ALT† 9 (29) –
Elevated blood urea‡ 8 (26) –
Elevated AST† 8 (26) –
Rash 7 (23) –
Dyspnea 9 (29) –
Muscle spasms 8 (26) –
Cough 9 (29) –
Pain 9 (29) –
Upper respiratory tract infection 11 (35) –
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*According to the National Cancer Institute Common Terminology
for Adverse Events, Version 3.0. (National Cancer Institute 2006).
†>39 the upper limit of normal range.
‡Greater than the upper limit of normal range.
Table III. Summary of clinical response, according to the modified
European Group for Blood and Bone Marrow Transplant criteria
(Bladé et al, 1998).
Response (n = 30) n (%)
Duration, weeks
(range)
nCR 4 (13) 117+, 115+, 114, 24
VGPR 3 (10) 141, 34, 17
PR 8 (27) 34 (11–112)
PR 15 (50) 43 (11–141)
MR 7 (23) 41 (9–114)
 MR 22 (73) 45 (9–141)
SD* 6 (20) 14 (8–19)
PD 2 (7) 8, 4
nCR, near complete response; VGPR, very good partial response; PR,
partial response; MR, minimal response; SD, stable disease; PD, pro-
gressive disease; ORR, overall response rate.
*SD defined as <25% reduction in M-protein.
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two of six patients achieved PR or better, and four achieved
MR or better.
Survival analysis
After a median follow up of 30 months (range, 3·4–
51·3 months), median PFS was 10·8 months in all evaluable
patients and 11·7 months in patients who achieved a MR or
better (Fig 1A). Median OS was 30·6 months in all evaluable
patients and was not reached in patients who achieved at
least a MR or better (Fig 1B). As of 10 July 2011, 15 of the
30 evaluable patients were still alive, and seven patients had
not progressed. For those patients who achieved a MR or
better, nine patients had died and 17 patients had pro-
gressed. Patients with relapsed but not refractory disease had
longer median PFS and OS than patients with refractory dis-
ease (27·7 vs. 3·9 months, P = 0·0002; not reached versus
16·7 months, P = 0·0006; Fig 2).
Among the 22 thalidomide-exposed patients, of which
59% were refractory to both thalidomide and dexametha-
sone, median PFS and OS were 5·2 and 17·2 months,
respectively. Median PFS was significantly higher in thalid-
omide-relapsed patients than in thalidomide-refractory
patients (12·9 vs. 3·9 months; P = 0·0145; Fig 3A). Median
OS was not reached in thalidomide-relapsed patients and
was 16·7 months in thalidomide-refractory patients
(P = 0·0568; Fig 3B). As of July 10, 2011, 15 patients who
had received prior thalidomide had died, and 19 had pro-
gressed.
Assessment of phospho-Akt
In exploratory analysis, baseline bone marrow phospho-Akt
immunostaining was assessed in 13 patients, 11 were positive
for phospho-Akt (range of 10–90% plasma cells; Fig S2A–D).
PFS was longer in patients with high immunostaining of
phospho-Akt than those with low staining (25 vs. 5 months,
respectively, P = 0·17; Fig S2E).
Phospho-Akt immunostaining postcycle 1 was also
assessed in seven of the 13 patients. Three of these seven
patients achieved at least PR, which was associated with a
change from baseline positive phospho-Akt to either not
detectable or decreased immunostaining. In the four other
patients, there was no detectable change in phospho-Akt
staining; none achieved a PR or better (data not shown).
(A)
(B)
Fig 1. Kaplan–Meier plot of PFS (A) and OS (B) in all evaluable
patients (n = 30) and patients who achieved MR (n = 22).
Abbreviations: CI, confidence interval; MR, minimal response; NR,
not reached; OS, overall survival; PFS, progression-free survival.
(A)
(B)
Fig 2. Kaplan–Meier plot of PFS (A) and OS (B) in relapsed but non-
refractory patients (n = 17) and relapsed/refractory patients
(n = 13). Abbreviations: CI, confidence interval; NR, not reached;
OS, overall survival; PFS, progression-free survival.
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Discussion
This is the first clinical trial to assess perifosine–lenalidomide–
dexamethasone in patients with relapsed or relapsed/refractory
MM. The combination was well tolerated with manageable
AEs, and demonstrated encouraging and durable antitumour
activity in this patient population, which included 47%
patients with relapsed/refractory disease.
Perifosine, the first in class Akt inhibitor, has emerged as
a promising new drug in the search for new anti-myeloma
therapies, beyond proteasome inhibitors and immunomodu-
latory drugs. Encouraging results achieved with perifosine
plus bortezomib–dexamethasone (Richardson et al, 2011) in
relapsed/refractory MM, has led to the development of an
ongoing Phase III trial with this 3-drug combination (www.
clinicaltrials.gov NCT01002248). The current study was
based on a rationale that perifosine may enhance the activ-
ity of lenalidomide and dexamethasone. This 3-drug combi-
nation may also provide a more patient-friendly all-oral
drug regimen in MM. In this context, establishing that the
regimen is well tolerated, with no overlapping toxicities was
important. DLTs were limited and the MTD was not
reached at maximum planned doses. Extended use was
associated with gastrointestinal toxicities and fatigue, which
did lead to dose attenuations in later treatment cycles.
However, these toxicities were easily manageable and
patients who responded tolerated the treatment well for
extended periods of time, meeting the objectives of a
patient-friendly all-oral regimen.
Is this 3-drug regimen also fulfilling a promise of being
more efficacious than the 2-drug combination of lenalido-
mide–dexamethasone? Because of the design of this Phase I
study, the evaluation of efficacy was limited to providing
preliminary evidence and was not powered to evaluate the
impact of adding perifosine to lenalidomide–dexamethasone
in terms of efficacy and duration of response. In addition,
comparison with historical data on lenalidomide–dexametha-
sone in relapsed MM (MM-009 and MM-010), is limited
(Dimopoulos et al, 2007; Weber et al, 2007). The patient
population in these studies included mainly relapsed rather
than refractory disease, and dexamethasone was used at
higher doses, which may be associated with greater efficacy
(Rajkumar et al, 2010b), whereas the patient population
enrolled into the current study was more pretreated and
included a significant proportion (47%) of refractory
patients. Therefore, an observed response rate of at least PR
or better of 50% plus time-to-event data, PFS (10·8 months)
and OS (30·6 months) are encouraging. A subset analysis of
non-refractory patients enrolled into our study, more compa-
rable to the patient population enrolled into MM-009 and
MM-010 studies, indicated a PR or better rate of 70%, and
PFS was 27·7 months, which appears improved when com-
pared to historical data with lenalidomide–dexamethasone
(Dimopoulos et al, 2007; Weber et al, 2007). Efficacy and
survival data, in the current study, for those patients previ-
ously treated with thalidomide are also encouraging, even
though a high proportion (59%) of patients were refractory
to thalidomide and dexamethasone, making comparison to
historical data difficult (Dimopoulos et al, 2007; Weber et al,
2007; Kumar et al, 2008).
Our exploratory pharmacodynamic study data (see
Appendix S1, Table SI, and Fig S1) suggest that the clinical
efficacy of perifosine–lenalidomide–dexamethasone is posi-
tively associated with phospho-Akt; the activity of the 3-drug
combination appeared to be more likely in patients with
higher baseline phospho-Akt. Although this observation is
based on just a few patients, the correlative data could rep-
resent the first steps towards the rational selection of indi-
vidualized therapy with Akt inhibitors. The data also suggest
that perifosine may be particularly effective in patients with
Akt-dependent MM, a sub-group of MM (Zollinger et al,
2008). Additional studies are ongoing to investigate the
potential relationship between perifosine activity and phos-
pho-Akt. Findings may show whether patients with an acti-
vated Akt genotype would benefit in particular from the
addition of perifosine, therefore raising the possibility of




Fig 3. Kaplan–Meier plot of PFS (A) and OS (B) in thalidomide-
relapsed (n = 9) and thalidomide-refractory patients (n = 13).
Abbreviations: CI, confidence interval; NR, not reached; OS, overall
survival; PFS, progression-free survival.
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Other Phase I/II studies have investigated whether the
addition of a third agent, such as doxorubicin (Knop et al,
2009), vorinostat (Siegel et al, 2009), or cyclophosphamide
(Schey et al, 2010), can enhance the activity of lenalidomide–
dexamethasone in patients with relapsed and/or refractory
MM. As with the current study, it has been difficult to dem-
onstrate improved efficacy and survival of the 3-drug combi-
nations over the lenalidomide–dexamethasone regimen, due
to a lack of comparable patient populations. Therefore,
trials will be required to directly compare emerging 3-drug
combinations in patients with relapsed and relapsed/
refractory disease.
In conclusion, perifosine–lenalidomide–dexamethasone
shows acceptable tolerability and encouraging clinical activity
in patients with relapsed or relapsed/refractory MM, consid-
ering that close to 50% of the enrolled patients were refrac-
tory to prior treatments. While the study was neither
designed nor powered to assess an impact of an addition of
perifosine on efficacy data, the combined clinical and correla-
tive data appear to suggest that adding perifosine to
lenalidomide–dexamethasone may provide potential for
added clinical benefit in this setting (Jakubowiak et al, 2007).
Based on these findings, further clinical evaluation, including
a head-to-head study of perifosine–lenalidomide–dexametha-
sone versus lenalidomide–dexamethasone, and the evaluation
of an impact of pretreatment Akt expression and number of
prior therapies is warranted and may complement the ongo-
ing randomized Phase lll study evaluating perifosine with
bortezomib and dexamethasone (www.clinicaltrials.gov
NCT01002248).
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Fig S1. Cultured NCI-H929 cell survival in the MTT assay
following incubation for 72 h with perifosine–lenalidomide–
dexamethasone (at concentrations of 2.5 lmol/l, 500 nmol/l,
and 20 nmol/l, respectively), lenalidomide–dexamethasone,
or perifosine alone.
Fig S2. Phospho-Akt immunostaining in bone marrow
samples. Representative samples of immunohistochemical
staining for CD138 and phospho-Akt in bone marrow core
biopsies of patients with high or low phospho-Akt are shown
(A–D).
Table S1. Combination indices (according to CalcuSyn
analysis) derived from MTT cell survival assays with cultured
NCI-H929 MM cells following incubation for 72 hours with
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methasone.
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